These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1973057)

  • 1. Differences in [3H]-spiperone binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic patients.
    Grodzicki J; Pardo M; Schved G; Schlosberg A; Fuchs S; Kanety H
    Biol Psychiatry; 1990 Jun; 27(12):1327-30. PubMed ID: 1973057
    [No Abstract]   [Full Text] [Related]  

  • 2. Uptake of 3H-spiperone by lymphocytes in schizophrenia.
    Itzchaky S; Lerer B; Ebstein RP
    J Psychiatr Res; 1989; 23(3-4):221-7. PubMed ID: 2635219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects.
    Wodarz N; Fritze J; Riederer P; Beckmann H
    Biol Psychiatry; 1993 May; 33(10):727-33. PubMed ID: 8353168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.
    Coppens HJ; Slooff CJ; Paans AM; Wiegman T; Vaalburg W; Korf J
    Biol Psychiatry; 1991 Apr; 29(7):629-34. PubMed ID: 1675892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Association between uptake to lymphocytes from schizophrenic patients and therapeutic efficacy].
    Shimogawa S; Kaku H; Yoshimoto S; Nakane Y
    Yakubutsu Seishin Kodo; 1986 Jun; 6(2):239-46. PubMed ID: 2877529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.
    Laufer N; Spivak B; Holdengreber V; Zipser J; Kosower N; Ragolsky M; Weizman A
    Clin Neuropharmacol; 1999; 22(2):110-4. PubMed ID: 10202608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sequestration of [3H]spiperone by lymphocytes in schizophrenics and their first-degree relatives: a limited vulnerability marker?
    Griffiths RS; Chung-a-on KO; Griffiths KD; Payne JW; Davies JI
    J Psychiatr Res; 1992 Jan; 26(1):77-84. PubMed ID: 1560411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of schizophrenia: a review.
    Sigmundson HK
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S70-5. PubMed ID: 7533053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R
    Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic-like and antipsychotic effects of gamma-type endorphins.
    Van Ree JM; Verhoeven WM; Van Praag HM; De Wied D
    Mod Probl Pharmacopsychiatry; 1981; 17():266-78. PubMed ID: 6173744
    [No Abstract]   [Full Text] [Related]  

  • 16. Alteration of dopamine receptors in the caudate nucleus and the putamen in schizophrenic brain.
    Mjörndal T; Winblad B
    Med Biol; 1986; 64(6):351-4. PubMed ID: 2881030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.
    Kornhuber J; Riederer P; Reynolds GP; Beckmann H; Jellinger K; Gabriel E
    J Neural Transm; 1989; 75(1):1-10. PubMed ID: 2563750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 receptors in substantia nigra in schizophrenia.
    Owen R; Owen F; Poulter M; Crow TJ
    Brain Res; 1984 May; 299(1):152-4. PubMed ID: 6144367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.